Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma

International Journal of Gynecological Pathology

Volumn 17, Issue 2, 1998, Pages 129-134

  Soslow, Robert A ^a   Shen, Peter U Fu ^a   Chung, Marilda H ^a   Isacson, Christina ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Endometrial carcinoma; mdm2; p53; Papillary serous carcinoma

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENDOMETRIUM CARCINOMA; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

EID: 0031945804     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199804000-00006     Document Type: Article

References (37)

1. Lee KR. Recurrence in noninvasive endometrial carcinoma. Am J Surg Pathol 1991;15:965-73.
2. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990;3:120-8.
3. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992;16:600-10.
4. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
5. Nielsen AL, Thomsen HK, Nyholm HCJ. Evaluation of the reproducibility of the revised 1988 International Federation of Gynecology and Obstetrics grading system of endometrial cancers with special emphasis on nuclear grading. Cancer 1991;68:2303-9.
6. Ambros RA, Vigna PA, Figge, et al. Observation on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer 1994;73:1686-92.
7. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98:81-7.
8. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52: 1622-7.
9. Jiko K, Sasano H, Ito K, et al. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. Anticancer Res 1993;13:305-8.
10. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.
11. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-74.
12. Enomoto T, Fujita M, Inoue M, et al. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 proto-oncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 1993;53:1883-8.
13. Ambros R, Ross JS, Kallakury BVS, et al. p53 Gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemistry. Mod Pathol 1995;8:441-5.
14. Reich NC, Oren M, Levine AJ. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 1983;3: 2143-50.
15. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
16. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
17. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-8.
18. Momand J, Zambetti GP, Olson DC, George DL, Levine AJ. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
19. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
20. Werness BA, Levine AJ, Howley PM. The E6 proteins encoded by human papillomavirus type 16 and 18 can complex p53 in vitro. Science 1990;248:76-9.
21. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
22. Leach FS, Tokino T, Meltzer P, et al. P53 mutation and mdm-2 amplification in human soft tissue sarcomas. Cancer Res 1993;53: 2231-4.
23. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736-9.
24. Marchetti A, Buttitta F, Girlando S, et al. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 1995; 175:31-8.
25. Ambros RA, Sheehan CE, Kallakury BVS, et al. mdm2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Mod Pathol 1996;9:1165-9.
26. Shen P, Chung M, Isacson C, Soslow RA. Inverse immunohistochemical expression of p53 and mdm-2 in uterine serous carcinoma versus high grade endometrioid carcinoma suggests different pathogenetic pathways [abstract]. Mod Pathol 1997;10:109A.
27. Abeler VM, Kjorstad KE, Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int J Gynecol Cancer 1992;2:9-22.
28. Hendrickson M, Martinez A, Ross J, Kempson R, Eifel P. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
29. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium. I: Papillary adenocarcinoma: A clinical pathological study of 46 cases. Am J Clin Pathol 1982;77:534-40.
30. Chen JL, Trost DC, Wilkinson EJ. Endometrial papillary adenocarcinomas: Two clinicopathological types. Int J Gynecol Pathol 1985;4:279-88.
31. Ward BG, Wright RF, Free K. Papillary carcinomas of the endometrium. Gynecol Oncol 1990;39:347-51.
32. Abeler VM, Kjorstad KE. Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol 1990;39:266-71.
33. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study of 100 cases with emphasis on the prognostic significance of associated endometrial carcinoma, absence of invasion and concomitant ovarian carcinoma. Gynecol Oncol 1992;47:298-305.
34. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological Typing of Female Genital Tract Tumours 2nd ed. Berlin: Springer-Verlag, 1994.
35. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-7.
36. Creasman WT. Announcement, FIGO stages: 1988 revisions. Gynecol Oncol 1989;35:125-7.
37. Remmele W, Schicketanz K-H. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 1993;189:862-6.